Icon Bioscience Reports Last Patient Out in its Phase 3 Study Of IBI-10090 as a Dropless, Sustained-released Therapeutic for Inflammation Associated With Cataract Surgery

IBI-10090 Is The First Drug Candidate Utilizing the Verisome®Delivery Technology

Sunnyvale, CA (OCTOBER 6, 2014) – Icon Bioscience, Inc., a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care therapeutics, today announced that the last patient has completed treatment in its pivotal Phase 3 study IBI-10090. Top-line data is expected to be reported in the fourth quarter of 2014. Employing Icon’s Verisome technology, IBI-10090 is designed to provide a controlled, sustained-release formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered immediately following cataract surgery.

Over three million cataract surgeries are performed annually in the US alone and the current standard of care for inflammation associated with the surgery involves a comparatively burdensome process of patient administered eye drops applied topically several times a day over an extended time period. “Thus, the superior drug delivery benefit of IBI-10090 addresses a significant product opportunity in a fairly large ophthalmic pharmaceutical space,” said David S. Tierney, MD, Icon’s President & CEO. The Phase 3 study of IBI-10090 involved 390 patients in a randomized, double blind, andplacebo-controlled study. “A previous phase 2 study, demonstrated a highly favorable efficacy and safety profile, and we eagerly await results of the completed Phase 3 study,” noted Tierney.

About Icon Bioscience and Verisome®

Icon Bioscience, Inc. is a privately held specialty biopharmaceutical company focused on the development and commercialization of unique ophthalmic pharmaceuticals based on its patented and proprietary Verisome® drug delivery technology. The technology encompasses a broad number of related, but distinct drug delivery systems capable of incorporating an extensive range of active agents, including small molecules, proteins and monoclonal antibodies. Moreover, this drug delivery platform is a highly advanced, yet elegantly formulated system for controlling the release of medication within the eye for up to a year through the administration of a single injection. The technology’s exceptional versatility can support products individually formulated to meet the particular clinical requirements of a given active agent targeting a specific ophthalmic disease. Icon is actively developing a broad portfolio of specialty pharmaceuticals targeting several ophthalmic indications, including macular edema, glaucoma, age-relate macular degeneration and cataract surgery.